IMC Licensing

Innovative Med Concepts (IMC) is a clinical-stage biotechnology company focused on developing novel combination therapies for chronic sensory and fatiguing disorders, such as fibromyalgia and irritable bowel syndrome (IBS). The company's therapeutic approach is based on the hypothesis that these conditions are driven by the chronic reactivation of latent Herpes Simplex Virus Type 1 (HSV-1) in the sensory ganglia. Their lead candidate, IMC-1, is a proprietary fixed-dose combination of the antiviral famciclovir and the COX-2 inhibitor celecoxib, designed to synergistically suppress viral replication and associated neuroinflammation. IMC is currently advancing IMC-1 through Phase 3 clinical trials for fibromyalgia, representing a potentially transformative treatment paradigm for patients with limited options. The company operates as a development-focused entity, actively seeking strategic licensing partnerships to commercialize its pipeline.